Telemetry Investments L.L.C. Takes Position in Corvus Pharmaceuticals Inc (CRVS)
Telemetry Investments L.L.C. acquired a new position in shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 135,123 shares of the company’s stock, valued at approximately $496,000.
Several other hedge funds have also recently modified their holdings of CRVS. Acadian Asset Management LLC grew its stake in shares of Corvus Pharmaceuticals by 59.2% during the 3rd quarter. Acadian Asset Management LLC now owns 34,229 shares of the company’s stock valued at $293,000 after buying an additional 12,735 shares during the period. BlackRock Inc. lifted its holdings in Corvus Pharmaceuticals by 7.8% in the 3rd quarter. BlackRock Inc. now owns 1,206,520 shares of the company’s stock worth $10,350,000 after buying an additional 87,013 shares in the last quarter. Hikari Power Ltd lifted its holdings in Corvus Pharmaceuticals by 305.1% in the 4th quarter. Hikari Power Ltd now owns 130,000 shares of the company’s stock worth $477,000 after buying an additional 97,910 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $107,000. Finally, Credit Suisse AG acquired a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $194,000. 85.83% of the stock is currently owned by institutional investors.
Shares of NASDAQ:CRVS traded up $0.03 during midday trading on Friday, reaching $4.24. 34,534 shares of the company’s stock were exchanged, compared to its average volume of 100,658. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller acquired 10,000 shares of the business’s stock in a transaction dated Thursday, December 20th. The shares were acquired at an average price of $4.40 per share, with a total value of $44,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Leiv Lea acquired 24,700 shares of the business’s stock in a transaction dated Friday, December 21st. The stock was acquired at an average cost of $4.15 per share, for a total transaction of $102,505.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 74,700 shares of company stock valued at $278,105. 39.50% of the stock is owned by corporate insiders.
A number of equities research analysts recently weighed in on CRVS shares. ValuEngine downgraded shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Finally, Wedbush cut their target price on shares of Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $11.94.
Corvus Pharmaceuticals Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Read More: Technical Analysis
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.